14 February 2016

NZ resource group takes AIM

25/01/10

Aussie entrepreneur Ian Gowrie-Smith plans to float New Zealand offshore oil play Kea Petroleum with a £6m AIM funding.

Aussie entrepreneur Ian Gowrie-Smith plans to float New Zealand offshore oil play Kea Petroleum with a £6m AIM funding.

Veteran Aussie entrepreneur Ian Gowrie-Smith plans to float Kea Petroleum with a £6 million AIM funding.

Gowrie-Smith, a sometimes controversial but usually successful corporate player who founded UK drug groups Medeva and SkyePharma and floated Papua New Guinea-focused Rift Oil three years ago, is chairman of Kea, whose three exploration permits in New Zealand’s well established Taranaki and Northlands basins hold an estimated 686 billion cubic feet of gas and 36.5 million barrels of oil. Serial investor Nigel Wray and Mark Knopfler of the band ‘Dire Straits’, who both backed Rift Oil, are among pre-float investors who have put some £7.2 million into Kea since September at 5p a share.

That price compares with a hoped-for 8p for the AIM launch, says executive director David Lees, who says the company intends to start drilling in two months and aims to achieve first sales within a year. RBC Capital Markets is designated nominated adviser and broker to Kea, which struck a deal whereby Canada-based Methanex Corporation will fund one of the wells in exchange for a commercially priced off-take agreement for the gas and a share of development profits.

Lees, like chief executive officer Dr David Bennett a former Rift Oil luminary, argues the Taranaki and Northlands basins are notably more hospitable and better provided with infrastructure than Rift’s PNG prospects. Kea, which hopes to establish a £60 million AIM value with this float, has also applied for some offshore New Zealand licences.

Rift delivered its original AIM backers a three-fold return over four years when Talisman Energy took it over last year, though not all Gowrie-Smith ploys have fared that well. Investors in Kea, one of whose exploration wells is called Beluga, will be hoping for a similarly appetising payback this time.

Tags: AIM, Fundraisings, New Issues

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Gresham brings private equity expertise to small listed stocks 11/02/16

There are many smaller company funds out there; but the new management of Gresham House Strategic (AIM: GHS) is trying to stand out from the crowd by bringing a ‘private equity’ approach to the public market arena. For investors who supplement their own ‘DIY’ stock picking with selected funds, GHS could be an interesting option.

Diurnal to profit from orphan drugs 09/02/16

Drug developer Diurnal (AIM: DNL) joined AIM a couple of days before Christmas. It already has one product in final phase III clinical trials and another due to start them shortly. So revenue generation at Diurnal should be a lot closer than at many junior biotechs. If all goes according to plan lead product Infacort should hit the market in 2018.

Forbidden focuses on selling 05/02/16

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair! 04/02/16

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough 01/02/16

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced 29/01/16

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

More News